Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT04251806

Sleep-disordered Breathing in Infants With Myelomeningocele

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
173 (actual)
Sponsor
University of Michigan · Academic / Other
Sex
All
Age
2 Years
Healthy volunteers
Not accepted

Summary

This study aims to determine whether the risk for sleep-disordered breathing in infants with myelomeningocele (a severe form of spina bifida) differs among those who underwent fetal vs. postnatal surgery, and to examine the link between sleep-disordered breathing and neurodevelopment.

Detailed description

Myelomeningocele (MMC), the most severe form of spina bifida, is characterized by exposure of the spinal cord through a spinal defect. Sleep-disordered breathing (SDB) is common in children with MMC and is a risk factor for sudden death. Abnormal sleep physiology is likely multifactorial, related to MMC level, brainstem dysfunction, musculoskeletal factors, and pulmonary abnormalities. In infants, SDB may be treatable with oxygen, caffeine, or positive airway pressure. Yet, SDB screening is not routine, even in centers with specialized MMC programs. Evaluation of sleep in neonates who require intensive care is an emerging opportunity with potential for major impact on health and quality of life for affected children. As SDB and abnormal sleep are potentially treatable, early assessment and intervention could become an integral part of a multidisciplinary treatment strategy to optimize long-term medical and neurodevelopmental outcomes.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTneonatal polysomnographyThis procedure will allow the detection of sleep-disordered breathing in the neonatal period.
DIAGNOSTIC_TEST2-year Bayley ExamThis procedure will evaluate neurodevelopmental outcomes.
DIAGNOSTIC_TEST2-year polysomnographyThis procedure will allow the detection of sleep-disordered breathing at 2 years of age.

Timeline

Start date
2020-07-21
Primary completion
2024-04-25
Completion
2026-07-01
First posted
2020-02-05
Last updated
2026-03-30

Locations

9 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT04251806. Inclusion in this directory is not an endorsement.